STAT+: Roivant is one of the savviest dealmakers in biotech. It also has a secret weapon

The success of the company’s lung disease drug in a mid-stage study is a testament to its approach Molly Ferguson/STAT Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Roivant has proven to be one of the savviest dealmakers in biotech, evidenced once again this week by the strong efficacy achieved by its pipeline drug mosliciguat in a Phase 2 study of pulmonary hypertension associated with interstitial lung disease, or PH-ILD. As I wrote Tuesday, the study results could open up a new way to treat the serious lung disease and bolster Roivant’s financial health with a second blockbuster medicine. The drug’s origins are another fascinating aspect to the story. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.